Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $8.02M (cash outflow) rose 10.3% year over year, ahead of the -25.4% change in trailing-twelve-month net income. Sequentially, it fell 11.7% from the prior quarter. Over 3 fiscal years it compounded at -22.3% a year.

Context

  • Net income amounted to 1817.1% of revenue in FY2025, down 3687.2 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$10.78M (-63.7%) for the fiscal year ending Dec 2026, a slowdown from the -47.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.02M-11.7% QoQ
Last fiscal yearDec 2025
-$29.67M-47.6% YoY
LTMMar 2026
-$31.7M-25.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.3%+39.8%+29.5 pp
1 year-47.6%-63.7%-16.1 pp
3-year CAGR-22.3%-27.9%-5.5 pp
5-year CAGR-25.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(29.67M) USD
Year-over-year change
+47.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.4% is the lowest of 9, against a peer median of +9.8%.
  • Net income amounts to 1000.2% of revenue for RANI, versus a peer median of 1764.5%.
RANI Competitors
Net Income for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$147.39M USD+11.7%+4.0%839.5%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$123.33M USD+55.2%-13.9%356.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$84.53M USD+68.1%+22.9%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.36M USD+31.7%+2.6%3832.0%
MOLNMolecular Partners AGLTM Mar 2026CHF 64.16M CHF+7.8%——
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44.76M USD-8.4%+5.8%8526.1%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$40.19M USD-21.6%+11.9%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$31.7M USD-25.4%-22.3%1000.2%
Peer median (excluding RANI) —+9.8%+4.0%1764.5%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.